Cargando…
Efficacy of Dexrazoxane in Cardiac Protection in Pediatric Patients Treated With Anthracyclines
Cancer is one of the leading causes of morbidity and mortality in the pediatric population with the most common cancer being acute lymphoblastic leukemia. One of the most common drugs used in the treatment is the anthracycline group of chemotherapeutic agents, and a major side effect is cardiotoxici...
Autores principales: | Rahimi, Parya, Barootkoob, Behsheed, ElHashash, Ahmed, Nair, Arun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cureus
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10166653/ https://www.ncbi.nlm.nih.gov/pubmed/37182052 http://dx.doi.org/10.7759/cureus.37308 |
Ejemplares similares
-
Efficacy of Dexrazoxane in Preventing Anthracycline Cardiotoxicity in Breast Cancer
por: Macedo, Ariane V.S., et al.
Publicado: (2019) -
Anthracycline extravasation injuries: management with dexrazoxane
por: Jordan, Karin, et al.
Publicado: (2009) -
Dexrazoxane for Preventing Anthracycline Cardiotoxicity in Children with Solid Tumors
por: Choi, Hyoung Soo, et al.
Publicado: (2010) -
Cardiac Protective Effects of Dexrazoxane on Animal Cardiotoxicity Model Induced by Anthracycline Combined With Trastuzumab Is Associated With Upregulation of Calpain-2
por: Zhang, Sheng, et al.
Publicado: (2015) -
Dexrazoxane-afforded protection against chronic anthracycline cardiotoxicity in vivo: effective rescue of cardiomyocytes from apoptotic cell death
por: Popelová, O, et al.
Publicado: (2009)